Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
Abstract Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined. However, it is necessary to take into account all the properties of propranolol to select a d...
Guardado en:
Autores principales: | Laura Brohée, Olivier Peulen, Betty Nusgens, Vincent Castronovo, Marc Thiry, Alain C. Colige, Christophe F. Deroanne |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/76f47ad4a6c14361aa10363a8d4226c1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
por: L. E. Anselmino, et al.
Publicado: (2021) -
ROLE OF THE REGULATORY T CELLS IN PROGRESSION OF PROSTATE CANCER
por: S. V. Popov, et al.
Publicado: (2019) -
Updates on Molecular and Biochemical Development and Progression of Prostate Cancer
por: Omar Fahmy, et al.
Publicado: (2021) -
Sympathetic signaling facilitates progression of neuroendocrine prostate cancer
por: Shubham Dwivedi, et al.
Publicado: (2021) -
MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance
por: Nikita Sushentsev, et al.
Publicado: (2021)